Diabetes · Houston area, TX
Diabetes studies in Houston area, TX
56 recruiting studies have a site in the Houston area. This page includes nearby cities such as Pasadena, Sugar Land, The Woodlands, Katy.
56 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersPhase 1
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
Ocugen
- Location
- Bellaire, TX + 4 other US sites
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteersPhase 3
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Location
- Austin, TX + 55 other US sites
- Eligibility basics
- Ages 18–79
- RecruitingPhase 3
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
Merck Sharp & Dohme LLC
- Location
- Austin, TX + 27 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)
Merck Sharp & Dohme LLC
- Location
- Arlington, TX + 18 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
AstraZeneca
- Location
- Houston, TX + 12 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy
Biomea Fusion Inc.
- Location
- Austin, TX + 19 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
Novo Nordisk A/S
- Location
- Houston, TX + 13 other US sites
- Eligibility basics
- Ages 10–18
- RecruitingPhase 2
Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus
Hanmi Pharmaceutical Company Limited
- Location
- Tomball, TX + 19 other US sites
- Eligibility basics
- Ages 18–75
- Recruiting
Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial
Sonavex, Inc.
- Location
- Dallas, TX + 19 other US sites
- Eligibility basics
- Ages 18–84
- RecruitingPhase 2
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
Boehringer Ingelheim
- Location
- Austin, TX + 21 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2/Phase 3
Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema
AbbVie
- Location
- Austin, TX + 36 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases
Khondrion BV
- Location
- Houston, TX
- Eligibility basics
- Ages 18+
- RecruitingPhase 1/Phase 2
A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated
Boehringer Ingelheim
- Location
- Austin, TX + 24 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
Boehringer Ingelheim
- Location
- Austin, TX + 56 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
The RESET System Pivotal Clinical Trial (Protocol Revision K)
Morphic Medical Inc.
- Location
- Atascocita, TX + 25 other US sites
- Eligibility basics
- Ages 22–65
- RecruitingPhase 3
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
Sanofi
- Location
- Houston, TX + 33 other US sites
- Eligibility basics
- Ages 1–25
- RecruitingPhase 2
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
SAb Biotherapeutics, Inc.
- Location
- Dallas, TX + 20 other US sites
- Eligibility basics
- Ages 5–40
- RecruitingPhase 3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
Hoffmann-La Roche
- Location
- Bellaire, TX + 43 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Hoffmann-La Roche
- Location
- Brownsville, TX + 44 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
Pfizer
- Location
- Houston, TX + 29 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).
4D Molecular Therapeutics
- Location
- Austin, TX + 8 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
Eli Lilly and Company
- Location
- Houston, TX + 24 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease
Regeneron Pharmaceuticals
- Location
- Arlington, TX + 55 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Eli Lilly and Company
- Location
- Austin, TX + 59 other US sites
- Eligibility basics
- Ages 18+
Who these studies look for
Studies commonly set an HbA1c range, a diagnosis duration and a list of allowed or excluded medications. Some also recruit people without diabetes as a comparison group.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.